John Dawson, CEO of Alliance Pharma (LON:APH), explains to Proactiveinvestors that the deal to acquire 100% of the obstetric drug Syntometrine from Swiss giant Novartis is consistent with the company's strategy of acquiring well-established products that have good, steady cash flow. John says that the deal adds extra volume, extra sales, extra margins and flows down to profit ' very nicely'. The deal also takes APH into new territories. The US$11.5mln purchase price still leaves the company with access to £10mln in funds from its bank to pay for future deals.
Alliance Pharma wants to do 'more of the same' after Novartis deal
Quick facts: Alliance Pharma PLC
Price: 82.8 GBX
Market Cap: £438.42 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Alliance Pharma PLC named herein, including the promotion by the Company of Alliance Pharma PLC in any Content on the Site, the Company...FOR OUR FULL DISCLAIMER CLICK HERE